INMB - INmune Bio gets US patent covering use of XPro for neurological disorders

INmune Bio (NASDAQ:INMB) said it received a U.S. patent covering a use of its therapy XPro, which is being explored to treat central nervous system (CNS) disorders. The U.S. Patent No. 11,365,229 is titled “Methods of treating neurological diseases,” is directed toward use of Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, such as INmune's XPro, by peripheral administration for crossing the blood-brain barrier (BBB) and CNS diseases, the company said in a June 22 press release. The patent will provide coverage till Sept. 10, 2033, unless extended. The company noted that it is developing XPro, a pegylated DN-TNF composition also known as pegipanermin, to treat neurological disorders, including Alzheimer’s Disease , treatment-resistant depression and amyotrophic lateral sclerosis. "This patent is the product of real-life data using DN-TNF in both pre-clinical studies and the completed human Phase I study in Alzheimer’s Disease.  DN-TNF crosses the BBB to decrease neuroinflammation, decrease neurodegeneration, improve

For further details see:

INmune Bio gets US patent covering use of XPro for neurological disorders